Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

No Change to Product Information for Lapatinib Following Re-assessment of Data

Outcome of review of breast cancer study data by EMA
06 Apr 2020
Anticancer agents & Biologic therapy;  Breast cancer

On 27 March 2020, the European Medicines Agency (EMA) announced that the product information for lapatinib (Tyverb) will continue to state that no data are available on the effectiveness of Tyverb used together with an aromatase inhibitor compared with trastuzumab used with an aromatase inhibitor in breast cancer patients previously treated with trastuzumab.

In July 2018, results of a study involving women with hormone receptor (HR)-positive / human epidermal growth factor receptor (HER2)-positive breast cancer and whose disease had worsened despite previous treatment with trastuzumab were added to Tyverb’s product information. The results had indicated a benefit of Tyverb over trastuzumab when each medicine was used with an aromatase inhibitor. However, in April 2019, errors were detected in the data and they were removed from the product information.

During a procedure to re-assess the data, the contract research organisation where the data were analysed was inspected. The inspection found deficiencies in the systems and procedures for managing data and concluded that data handling did not comply fully with good clinical practice. In addition, the re-analysed data do not allow a conclusion on whether Tyverb is more effective than trastuzumab when either is combined with an aromatase inhibitor.

As a result, the study results will not be re-introduced into the product information for Tyverb. There are no consequences for the current authorised uses of the medicine in the treatment of breast cancer.

Tyverb is a cancer medicine used to treat patients with breast cancer expressing HER2.

The re-analysis of data was carried out as a type II variation (variation II/59). The incorrect information had previously been added to the prescribing information (in variation II/51) and subsequently removed (in variation IB/61).

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings